MBRX
HEALTHCAREMoleculin Biotech Inc
$2.48-0.01 (-0.40%)LIVE
Live · NASDAQ · May 9, Close
AI Insight
What's Moving MBRX Today?
No stock-specific AI insight has been generated for MBRX yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$1.79$28.61
$2.48
Fundamentals
Market Cap$13M
P/E Ratio—
EPS$-28.42
Dividend Yield—
Dividend / Share—
ROE-2.6%
Profit Margin—
Debt / Equity—
Trading
Volume54K
Avg Volume (10D)—
Shares Outstanding5.3M
MBRX News
21 articles- Moleculin Biotech Secures Strategic Additional Patent, Strengthening Global Positioning of AnnamycinYahoo Finance·May 8, 2026
- Moleculin’s Annamycin Extends Survival by More Than 60% in Metastatic Pancreatic Cancer Preclinical Models - Data Presented at AACR 2026Yahoo Finance·Apr 23, 2026
- Moleculin Announces Abstract Accepted for Poster Presentation at the 2026 ASCO Annual MeetingYahoo Finance·Apr 21, 2026
- Moleculin Releases Next CEO Corner Segment Highlighting Annamycin’s Non-Cardiotoxic ProfileYahoo Finance·Apr 7, 2026
- Scalable Biotech Manufacturing Unlocks a $14B MarketBenzinga·Mar 27, 2026
- Moleculin Hits 45 Subject Enrollment Milestone, Triggering Final Countdown to Mid-2026 MIRACLE Trial Data ReadoutYahoo Finance·Mar 23, 2026
- Moleculin Reports Full Year 2025 Financial Results and Confirms Highly Anticipated 45-Patient Interim Data Unblinding in Pivotal MIRACLE Trial On Track for Mid-2026Yahoo Finance·Mar 19, 2026
- Moleculin to Present at 38th Annual ROTH ConferenceYahoo Finance·Mar 17, 2026
- Moleculin Releases Next CEO Corner Segment Highlighting MIRACLE StudyYahoo Finance·Mar 11, 2026
- Moleculin Announces Exercise of Warrants for $8.3 Million Gross ProceedsYahoo Finance·Feb 19, 2026
- Moleculin MIRACLE Trial Delivers 40% Preliminary Blinded CRc Rate (n=30)Yahoo Finance·Feb 18, 2026
- Moleculin Announces Notice of Allowance for Japanese Patent Covering AnnamycinYahoo Finance·Feb 17, 2026
- Moleculin Launches CEO Corner Platform to Share Strategic InsightsYahoo Finance·Feb 13, 2026
- JTC Team Companies to Present in Webull Corporate Connect Webinar Series Happening February 10-11, 2026Yahoo Finance·Feb 9, 2026
- Moleculin to Participate in the Corporate Connect Webinar Series Virtual Conference Hosted by Webull FinancialYahoo Finance·Feb 5, 2026
- Moleculin Reports Independent Assessment Confirms No Cardiotoxicity of Annamycin in 90 SubjectsYahoo Finance·Jan 13, 2026
- Moleculin Accelerates Outlook Into 2026 With First Pivotal Trial Unblinding on Track, Global Trial Expansion, and Multiple Externally/IIT Funded Clinical ProgramsYahoo Finance·Jan 12, 2026
- Moleculin Announces Positive Results from Phase 1 Clinical Trial Evaluating WP1066 for the Treatment of Pediatric Recurrent Malignant Brain TumorsYahoo Finance·Dec 17, 2025
- Moleculin Announces Exercise of Warrants for $6.8 Million Gross ProceedsYahoo Finance·Dec 10, 2025
- Moleculin Announces Completion of Treatment for the 45 Patients in Pivotal “MIRACLE” Phase 3 AML Trial on Pace for Q1 2026Yahoo Finance·Dec 9, 2025
- Moleculin Announces New Annamycin Collaboration in Brain TumorsYahoo Finance·Dec 8, 2025
All 21 articles loaded
Price Data
Open$2.49
Previous Close$2.49
Day High$2.55
Day Low$2.48
52 Week High$28.61
52 Week Low$1.79
52-Week Range
$1.79$28.61
$2.48
Fundamentals
Market Cap$13M
P/E Ratio—
EPS$-28.42
Dividend Yield—
Dividend / Share—
ROE-2.6%
Profit Margin—
Debt / Equity—
Trading
Volume54K
Avg Volume (10D)—
Shares Outstanding5.3M
About Moleculin Biotech Inc
Moleculin Biotech, Inc., a clinical-stage pharmaceutical company, focuses on the development of cancer drug candidates for the treatment of highly resistant viruses and tumors in the United States. The company is headquartered in Houston, Texas.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeStock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—